目的 探讨微小RNA(miR)-129在胃癌组织中的表达及临床意义,并评估其在两种含铂化疗方案治疗晚期胃癌患者的价值.方法 检测52例胃癌患者福马林固定后石蜡包埋(FFPE)肿瘤组织及11例正常胃组织中miR-129的表达水平,并结合临床病理资料进行分析.结果 miR-129在胃癌组织中表达水平显著高于正常胃组织(P <0.01);miR-129的表达水平与既往治疗史比较差异有统计学意义(P<0.05).两个疗程后的疗效与晚期胃癌患者总生存时间明显相关,疗效为部分缓解(PR)、稳定(SD)、疾病进展(PD)的患者中位生存时间分别为8.41(5.29~11.52)、10.16(7.19~13.14)和5.10(3.11~7.08)个月.miR-129高表达患者与低表达患者中位生存时间分别为6.27(5.17 ~7.37)、8.74(6.71 ~10.77)个月,差异有统计学意义(P<0.05).miR-129高表达胃癌患者死亡风险比(HR)为miR-129低表达胃癌患者的2.77倍[95%可信区间(CI):1.12~6.87,P<0.05];SD、PD患者的HR分别为PR患者的0.95(95%CI:0.351 ~2.562,P>0.05)和6.02倍(95%CI:1.683 ~21.570,P<0.01).结论 胃癌组织中miR-129异常表达,其表达水平与晚期胃癌患者预后显著相关.
Objective To explore the microRNA (miR)-129 expression and its clinical significance in advanced gastric cancer,to evaluate the effectiveness of S-1/oxaliplatin vs.doxifluridine/oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in patients with advanced gastric cancer.Methods Total RNAs were extracted from normal and gastric tumor formalinfixed,paraffin embedded (FFPE) specimens.miR-129 expression was quantified using real-time quantitative polymerase chain reaction (real-time PCR) analysis.The correlation between the expression levels of miR-129 with clinical characteristics was analyzed by using chi-square test.Overall survival (OS) in patients with clinicopathological characteristics was analyzed using Kaplan-Meier and Log-rank test.The Cox proportional hazards model was performed to estimate Hazard risk (HR) with 95% confidence interval (CI) of the linking strength between the different clinical characteristics,the expression of miR-129,and death risk.Results The expression levels of miR-129 were significantly up-regulated in gastric tumors compared to normal gastric tissues (P < 0.01),and were significantly correlated with the previous treatment (P < 0.05),but not with gender,age,stage,tumor size and histological type by using Chi-square test.After two-course treatment,therapeutic effectiveness was significantly correlated with OS (P < 0.05),and Kaplan-Meier survival analysis revealed that the median survival time in patients with PR,SD and PD was 8.41 (5.29-11.52),10.16 (7.19-13.14) and 5.10 (3.11-7.08) months respectively.The up-regulation of the miR-129 expression was closely associated with shorter OS.The median OS in patient with low expression of miR-129 was 8.74 (6.71-10.77) months.In contrast,the median OS was only 6.27 (5.17-7.37)months in patients with the high expression of miR-129 (P < 0.05).The results of Cox model showed that the HR of patients SD,and PD was 0.95 (95% CI:0.351-2.562,P >0.05